Tissue Microarray

CD Genomics is a leading global company who can provide the best solution for worldwide customers in the field of Tissue Microarray. We have successfully accomplished many projects. We guarantee the finest results for our customers all over the world.

With the increasing application of next-generation sequencing (NGS) technology in tumors, gene sequencing and analyzing of tumors are no longer bottlenecks. The focus of gene research has shifted from structure to function. Technical requirements require simultaneous immunohistochemical staining and in situ hybridization of tumor samples from multiple patients at the same level. Traditional cancer tissue slicing technology, which embeds a tissue specimen in a wax block, can only cut out a section containing a tissue sample. It is not conducive to the rapid and efficient processing of a large number of tumor tissue specimens. At the same time, there are inevitably various errors between multiple tumor tissue sections. Tissue microarray (TMA) technology is widely used in cancer research under this background. The emergence of TMA, combined with gene microarray, plays a very complementary role in searching for disease genes. Genes screened by gene microarrays were used as probes, and then fluorescence in situ hybridization (FISH) was carried out between the probes and numerous tumor tissues in tissue chip to find out the relevant factors of tumorigenesis.

TMA is a kind of microarray made by arranging tens to thousands of small tissues neatly on a slide. It is another important bio-microarray after gene microarray and protein microarray. TMA, like gene microarray and protein microarray, is a high throughput and diverse analytical tool. For the first time, researchers can study one or more specific genes or related expression products in tissue samples of hundreds or even thousands of normal or disease and natural pathophysiological states at different stages of disease development. Tissue microarray overcomes the traditional pathological method that can only study sections one by one. It can obtain high throughput information of histomorphology, gene and protein expression on a single section. At the same time, it avoids the errors caused by different experimental conditions and has better comparability. TMA has obvious advantages over traditional tissue slices, such as large scale, high throughput and standardization. The experimental conditions of tissue samples on tissue microarray are identical, and it has excellent quality control. At the same time, it saves time and reagents. Under the unified experimental conditions, TMA can eliminate the intra-group or inter-batch differences caused by a series of complex factors, which greatly improves the accuracy of one-time multi-sample comparative analysis, and can analyze more subtle histological differences (e.g. protein expression profiles) among various tumor specimens1. Tissue samples collected on TMA are located accurately, and the number of invalid tissues is greatly reduced. At the same time, small samples collected by the organization will not destroy the original wax, which is conducive to the preservation of pathological files in hospitals. Finally, the fabrication and data analysis of array wax blocks in tissue chips can be automated, which greatly speeds up the experimental process. At present, there are still some shortcomings in the application of TMA in the field of cancer: because of the heterogeneity of tumor cells, there is some controversy whether the 0.6 mm diameter sample on TMA can fully represent the original tissue specimen. In addition, tissue chip manufacturing instruments and analysis systems are currently expensive and can not be widely used.

TMA technology can be combined with many other conventional techniques such as immunohistochemistry (IHC), nucleic acid in situ hybridization (ISH), FISH and in situ PCR, so that hundreds or thousands of tissue samples can be detected at genome, transcriptome, proteome and even cell level at one time. Researchers can effectively use hundreds of tissue specimens from natural or disease states to study the relationship between specific genes and their expressed proteins and diseases at a time. It is very important for molecular diagnosis, prognostic indicators and target location of treatment, screening of antibodies and drugs, etc. At present, TMA has become an important tool for the rapid transformation of molecular genetics, genomics and proteomics to clinical application. It has the advantages of small size, producing a large amount of information, high efficiency and low consumption, and good consistency of experimental conditions and comparability of results. This technique is not only suitable for histomorphological observation, but also for immunohistochemical and in situ hybridization studies. As a new biological research technology, TMA is showing its potential with its advantages. Its application has achieved the precise, fast and large amount of information detection of biological components such as cells, proteins and nucleic acids, which greatly improves the efficiency of the experiment. At the same time, combined with NGS, it has a good complementary role in searching for gene mutation and molecular markers of tumors. It provides batch detection of molecular markers for diagnosis and prognosis of tumors, and plays an irreplaceable role in cancer research. We believe that TMA will play a more and more important role in cancer research in the post-genome era as life science technologies rapidly evolve.

Our TMA Products

Experimental steps of TMA

  • TMA design.
  • Observe sample morphology using H&E stained sections.
  • Mark the corresponding position on the target tissue section and the corresponding paraffin tissue block.
  • Treat the 6 μm tissue section with 10% APES acetone solution.
  • Incubate slices at 37 ℃ overnight. Slices can be reserved at room temperature.
  • Provide experimental report.

CD Genomics offers high-quality services in Tissue Microarray. We can provide commercial, customized and semi-customized microarray services of TMA. We can provide a variety of paraffin and frozen microarray images, including normal, cancerous and metastatic types, and produce 3 to 5 new products per week. With a large and well-equipped scientist team, we are dedicated to collaborating with our clients around the world to meet your specific requirements. We have comprehensive design and production capabilities to provide broad and comprehensive services for academic and industrial research. If you are interested in our services, please contact us for more details.


  1. Saremi N, et al. (2018). "Application of Tissue Microarray in Esophageal Adenocarcinoma." Methods in Molecular Biology, 1756, 105-118.
Our products and services are for research purposes ONLY. We do not perform any private testing services that are not for laboratory use.
CD Genomics
Headquartered in New York, USA,
CD Genomics is cooperating with hundreds of institutions and marketing its products and services in multiple countries.

Contact Info




Inquiry Basket